Studies of tranexamic acid versus placebo, no treatment or any other medical therapy for the treatment of heavy uterine bleeding in non-pregnant women of reproductive age were eligible for inclusion. Heavy menstrual bleeding could be measured objectively or subjectively. Women could have uterine fibroids, dysfunctional uterine bleeding or menorrhagia secondary to an intrauterine device. Studies in women with gynaecological malignancies or post-menopausal bleeding were excluded. The primary outcome was objective reduction in idiopathic and non-functional menstrual bleeding. The secondary outcome was patient quality of life.
The included studies considered tranexamic acid in women with idiopathic menorrhagia, intrauterine device induced menorrhagia, dysfunctional uterine bleeding, uterine fibroids and unspecified menorrhagia. Treatment doses and durations varied across the studies. Comparators varied across the studies and included placebo, mefenamic acid and ethamsylate. The studies were published between 1970 and 2010.
It appeared that both authors were involved in study selection.